Perjeta® Receives FDA Approval for New Indication; Immediately Available for Order Through Onco360

NEW YORK - Oct. 1, 2013 - PRLog -- New York, NY - On September 30, 2013, the FDA granted Perjeta (pertuzumab) accelerated approval as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting).  Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer¹.

Onco360 is one of the select few pharmacies chosen to be in the limited distribution network for Perjeta, and has the product immediately available for prescription order to community and hospital-based oncologists nationwide.  Additionally, through its OncoSource^® program, Onco360 carries a comprehensive inventory of oral, injected, and infused oncology drugs, including over 20 limited distribution products and administrative supplies.

Perjeta’s new use is intended for patients with HER2-positive, locally advanced, inflammatory or early stage breast cancer (tumor greater than 2 cm in diameter or with positive lymph nodes) who are at high risk of having their cancer return or spread (metastasize) or of dying from the disease.  It is to be used in combination with trastuzumab and other chemotherapy prior to surgery and, depending upon the treatment regimen used, may be followed by chemotherapy after surgery.  Following surgery, patients should continue to receive trastuzumab to complete one year of treatment¹.

The original indication Perjeta was approved for in 2012 was for HER2-positive, advanced or latest stage (metastatic) breast cancer patients¹.

“The science of oncology pharmaceutical treatment is moving rapidly forward in new and exciting ways,” said Ron Bookman, SVP of Trade Channel Strategies for Onco360.  “As the leader in Oncology Pharmacy, our staff of highly trained and experienced Oncology Pharmacists are available to provide the same top-level clinical support people have come to expect from Onco360, to patients and oncologists that may be a fit for Perjeta’s new indication.”

Community and hospital-based oncologists can immediately place prescription orders for Perjeta, and other oncology pharmaceutical products by calling 877-662-6633.

For more information about Onco360 please visit Onco360.com (http://www.Onco360.com).

1. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370393.htm